Abirakast is a CYP17 inhibitor that suppresses androgen production, which fuels the growth of prostate cancer cells. It helps lower testosterone levels by blocking its biosynthesis in the testes, adrenal glands, and tumour tissue.
Recommended for:
Patients with metastatic castration-resistant prostate cancer (mCRPC)
Hormone-sensitive prostate cancer in combination therapy
Those who have or have not received prior chemotherapy
Metastatic castration-resistant prostate cancer (mCRPC)
Metastatic hormone-sensitive prostate cancer in combination with corticosteroids
Take orally, preferably on an empty stomach—either one hour before or two hours after meals. Usual dosage is 1g daily (4 x 250mg tablets), taken with prednisone under physician guidance.
Contraindications:
Severe hepatic impairment
Known hypersensitivity to abiraterone or formulation ingredients
Not intended for women or children
Side effects:
Hypertension, hypokalaemia, fluid retention
Elevated liver enzymes
Fatigue, nausea, bone pain
